Telomere Length Declines In Persons Living With HIV Before Antiretroviral Therapy Start But Not After Viral Suppression: A Longitudinal Study Over >17 Years.

Schoepf, Isabella C; Thorball, Christian W; Ledergerber, Bruno; Kootstra, Neeltje A; Reiss, Peter; Raffenberg, Marieke; Engel, Tanja; Braun, Dominique L; Hasse, Barbara; Thurnheer, Christine; Marzolini, Catia; Seneghini, Marco; Bernasconi, Enos; Cavassini, Matthias; Buvelot, Hélène; Arribas, José R; Kouyos, Roger D; Fellay, Jacques; Günthard, Huldrych F and Tarr, Philip E (2022). Telomere Length Declines In Persons Living With HIV Before Antiretroviral Therapy Start But Not After Viral Suppression: A Longitudinal Study Over >17 Years. The journal of infectious diseases, 225(9), pp. 1581-1591. Oxford University Press 10.1093/infdis/jiab603

[img]
Preview
Text
jiab603.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (1MB) | Preview
[img] Text
Schoepf_Telomere_length_HIV_2021_JID_1_.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.
Author holds Copyright

Download (848kB) | Request a copy

BACKGROUND

In people living with HIV (PWH), long-term telomere length (TL) change without/with suppressive antiretroviral therapy (ART) and the contribution of genetic background to TL are incompletely understood.

METHODS

We measured TL change in peripheral blood mononuclear cells by quantitative PCR in 107 Swiss HIV Cohort Study participants with longitudinal samples available both before and during suppressive ART. We applied mixed effects multi-level regression to obtain uni-/multivariable estimates for longitudinal TL dynamics including age, sex, and CD4:CD8 ratio. We assessed the effect of individual antiretrovirals and of an individual TL-polygenic risk score (TL-PRS; based on 239 single nucleotide polymorphisms) on TL in 798 additional participants from our previous longitudinal studies.

RESULTS

During untreated HIV infection (median observation, 7.7 [interquartile range, IQR, 4.7-11] years), TL declined significantly (median -2.12%/year; IQR, -3.48% to -0.76%/year; p=0.002). During suppressive ART (median observation, 9.8 [IQR, 7.1-11.1] years), there was no evidence of TL decline or increase (median +0.54%/year; IQR, -0.55% to +1.63%/year; p=0.329). TL-PRS contributed to TL change (global p=0.019) but particular antiretrovirals did not (all p>0.15).

DISCUSSION

In PWH, TL is associated with an individual polygenic risk score. TL declined significantly during untreated chronic HIV infection but no TL change occurred during suppressive ART.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine

UniBE Contributor:

Schöpf, Isabella Christina, Thurnheer Zürcher, Maria Christine

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1537-6613

Publisher:

Oxford University Press

Language:

English

Submitter:

Rahel Fuhrer

Date Deposited:

26 Jan 2022 10:55

Last Modified:

17 Dec 2022 00:25

Publisher DOI:

10.1093/infdis/jiab603

PubMed ID:

34910812

Uncontrolled Keywords:

HIV aging antiretroviral therapy longitudinal study polygenic risk score telomere length

BORIS DOI:

10.48350/163687

URI:

https://boris.unibe.ch/id/eprint/163687

Actions (login required)

Edit item Edit item
Provide Feedback